Zepbound Dosing Chart 2026: Every Dose, Week by Week

Starting Zepbound can feel confusing at first. There are six available strengths, but not every dose is intended to be used long term, and moving up too quickly can make nausea, vomiting, and other gastrointestinal side effects much harder to manage.

The good news is that the Zepbound schedule follows a fairly straightforward pattern: patients typically spend at least four weeks at each dose before moving higher. Treatment begins at 2.5 mg and can gradually increase to a maximum of 15 mg once weekly.

This guide explains the complete 2026 dosing schedule, which doses are used for maintenance, when a dose increase may make sense, what to do about missed injections, and why staying at a lower dose can sometimes be the better choice.

Zepbound Dosing Chart at a Glance

Zepbound (tirzepatide) uses a gradual dose-escalation schedule designed to help the body adjust to the medication.

Weeks

Weekly dose

Main purpose

1–4

2.5 mg

Starter dose

5–8

5 mg

First therapeutic/maintenance option

9–12

7.5 mg

Intermediate titration dose

13–16

10 mg

Maintenance option

17–20

12.5 mg

Intermediate titration dose

21+

15 mg

Maximum maintenance option

Zepbound is injected once per week. The starting dose is intentionally low, while later increases allow patients to gradually adjust to the medication's effects.

Importantly, 2.5 mg is a starting dose rather than a standard maintenance dose. The FDA-approved maintenance options for weight management are 5 mg, 10 mg, and 15 mg once weekly.

How the Zepbound Dose Escalation Works

The basic principle is simple: don't rush the dose increases.

Patients generally remain on each dose for at least four weeks before moving to the next level. This gives the body time to adjust and allows the prescriber to evaluate both weight-loss response and tolerability.

Weeks 1–4: 2.5 mg

Treatment typically begins with 2.5 mg once weekly.

This dose is primarily used to introduce tirzepatide gradually. It helps the body become accustomed to its GLP-1 and GIP receptor activity before stronger doses are introduced.

Some people experience nausea, reduced appetite, constipation, diarrhea, or other digestive symptoms even at this stage. If side effects are significant, the prescriber may recommend staying at the current dose longer rather than increasing immediately.

Weeks 5–8: 5 mg

After at least four weeks at 2.5 mg, many patients move to 5 mg once weekly.

This is the first dose that can serve as a long-term maintenance option. If someone is losing weight effectively and tolerating 5 mg well, there isn't automatically a reason to continue increasing.

The goal isn't to reach 15 mg as quickly as possible. The goal is to find the lowest dose that provides an appropriate response without causing unacceptable side effects.

Weeks 9–12: 7.5 mg

The next step is 7.5 mg once weekly when additional dose escalation is appropriate.

Unlike 5, 10, and 15 mg, the 7.5 mg strength is primarily an intermediate step in the standard escalation pathway.

It provides a smaller increase between 5 mg and 10 mg, giving the body additional time to adapt.

Weeks 13–16: 10 mg

Patients who need additional treatment beyond 5 mg may progress to 10 mg once weekly.

This is one of the FDA-approved maintenance doses. Clinical trial data show that moving from 5 mg to 10 mg can provide a meaningful additional reduction in body weight for many patients.

However, higher efficacy can also come with more gastrointestinal side effects, so the decision should be based on individual response rather than the assumption that higher is always better.

Weeks 17–20: 12.5 mg

12.5 mg once weekly is another intermediate dose.

It is primarily used to bridge the transition from 10 mg to the maximum 15 mg dose.

Not everyone needs this step. Someone who is doing well on 10 mg may remain there instead of continuing upward.

Week 21 and Beyond: 15 mg

15 mg once weekly is the highest approved Zepbound dose.

It may be considered for people who need additional weight reduction after lower doses and who tolerate the medication adequately.

Reaching 15 mg isn't a treatment requirement. Some patients may achieve their desired results at 5 or 10 mg and remain there.

Which Zepbound Doses Are Maintenance Doses?

There are three standard maintenance options:

5 mg once weekly
10 mg once weekly
15 mg once weekly

The best maintenance dose depends on factors such as weight-loss response, side effects, treatment goals, and overall health.

5 mg maintenance

Five milligrams may be appropriate when a patient is responding well and doesn't need additional medication exposure.

It can also be useful for people who experience troublesome side effects at higher strengths.

10 mg maintenance

Ten milligrams offers a middle ground between the lower and maximum doses.

In the SURMOUNT-1 trial, average weight loss was greater at 10 mg than at 5 mg, making it an important maintenance option for patients who need additional weight reduction.

15 mg maintenance

Fifteen milligrams is the maximum approved dose.

It may provide additional weight loss for some patients, but the difference between 10 mg and 15 mg is smaller than the increase seen when moving from 5 mg to 10 mg.

That means automatically choosing the highest dose isn't necessarily the best strategy.

What Are the 7.5 mg and 12.5 mg Doses For?

The 7.5 mg and 12.5 mg strengths can be confusing because they aren't among the standard maintenance doses.

They're best understood as transition doses.

The progression looks like this:

5 mg → 7.5 mg → 10 mg

and later:

10 mg → 12.5 mg → 15 mg

These intermediate strengths can make dose increases more gradual and potentially easier to tolerate.

A prescriber may sometimes choose a different individualized approach depending on a patient's response and side effects.

How Much Weight Can You Lose at Each Dose?

The SURMOUNT-1 clinical trial provides some of the most useful data for understanding the relationship between maintenance dose and average weight loss.

After 72 weeks of treatment, mean weight changes were approximately:

Treatment

Average weight change

Placebo

-3.1%

5 mg

-15.0%

10 mg

-19.5%

15 mg

-20.9%

These numbers are averages from a clinical trial, not a prediction of what one individual will lose.

For example, someone taking 5 mg may lose considerably more or less than the trial average. Starting weight, diet, physical activity, medical conditions, genetics, adherence, and treatment duration can all affect the outcome.

The biggest takeaway from the data

The difference between 5 mg and 10 mg was considerably larger than the difference between 10 mg and 15 mg.

That helps explain why 10 mg can be a practical long-term dose for many people. Going from 10 mg to 15 mg may provide additional benefit, but the improvement isn't necessarily dramatic for everyone.

When Should You Increase Your Zepbound Dose?

The standard schedule allows an increase after at least four weeks at the current dose.

A prescriber may consider moving you upward when:

You're tolerating the current dose well.
Your weight loss has slowed or isn't meeting your treatment goals.
Appetite control remains inadequate.
You haven't developed significant gastrointestinal symptoms.
Your overall health and treatment response support escalation.

But there are also good reasons not to increase.

When staying at your current dose may be better

You may not need a higher dose if:

You're continuing to lose weight.
Hunger and cravings are well controlled.
Side effects are still noticeable.
You're already close to your treatment goal.
Your current dose is working well for you.

A higher dose isn't automatically a better dose.

What If Zepbound Causes Nausea or Other Side Effects?

Digestive symptoms are among the most common issues associated with tirzepatide, particularly during dose increases.

Common symptoms can include:

Nausea
Diarrhea
Constipation
Vomiting
Abdominal discomfort
Reduced appetite

These symptoms often become more noticeable after increasing the dose.

If side effects are significant, don't increase the dose simply because you've reached the four-week mark. Talk with your prescriber about whether you should remain at the current strength for longer or step back.

Eating smaller meals, avoiding very large or high-fat meals, drinking enough fluids, and eating slowly may also make gastrointestinal symptoms easier to manage.

Can You Stay on a Lower Dose?

Yes. Not everyone needs to reach 15 mg.

For example, if 5 mg produces satisfactory appetite control and continued weight loss, a prescriber may decide that moving to 7.5 mg or 10 mg isn't necessary.

Similarly, someone who does well on 10 mg may not need to continue to 12.5 mg and 15 mg.

The appropriate maintenance dose is individualized rather than determined solely by the calendar.

What Happens If You Miss a Zepbound Dose?

The prescribing information provides a specific rule for missed injections.

If you remember the missed dose within four days (96 hours), take it as soon as possible.

If more than four days have passed, skip that dose and take your next injection on your regular scheduled day.

Do not take two doses close together to compensate for the missed injection.

Keeping injections at least 72 hours apart is important when changing the weekly injection day.

If you've missed several consecutive doses, contact your prescriber before restarting. After a longer interruption, you may need to return to a lower dose and gradually increase again.

Zepbound Storage and Pen Safety

Zepbound pens are designed for single use.

Before using the medication, check the strength printed on the carton and pen. Don't rely solely on the pen's color because different strengths can have similar visual characteristics.

Zepbound should generally be refrigerated according to the manufacturer's storage instructions, and it should not be frozen.

After using a single-dose pen, dispose of it properly in an appropriate sharps container.

What Happens If You Stop Zepbound?

Zepbound is generally considered a long-term treatment rather than a short-term weight-loss course.

Research from the SURMOUNT program has shown that stopping tirzepatide can result in significant weight regain. This doesn't mean everyone will regain all of the weight they lost, but it highlights an important point: maintaining weight loss often requires ongoing treatment and lifestyle support.

If you want to stop treatment, discuss the plan with your healthcare professional rather than abruptly changing your regimen on your own.

Zepbound Dosing With Diabetes

Tirzepatide is also available under the brand Mounjaro for type 2 diabetes.

Although both medications contain tirzepatide, the indication and prescribing context differ. People taking tirzepatide for diabetes may also be using insulin or sulfonylureas, which can affect blood glucose and hypoglycemia risk.

Anyone taking multiple glucose-lowering medications should have their treatment plan reviewed by their healthcare provider before changing doses.

What the SURMOUNT Trials Tell Us About Dosing

The Zepbound dosing schedule is supported by the broader SURMOUNT clinical trial program.

SURMOUNT-1

SURMOUNT-1 evaluated adults with obesity or overweight plus weight-related health conditions who did not have type 2 diabetes.

The study demonstrated substantial average weight loss with weekly tirzepatide at 5, 10, and 15 mg compared with placebo.

SURMOUNT-2

SURMOUNT-2 studied people with obesity and type 2 diabetes.

Weight loss was still substantial, although average results differed from those seen in participants without diabetes.

SURMOUNT-3

SURMOUNT-3 examined tirzepatide after an intensive lifestyle intervention, showing that medication can provide additional weight-loss benefits alongside structured lifestyle changes.

SURMOUNT-4

SURMOUNT-4 examined what happens after treatment withdrawal. Participants who stopped tirzepatide experienced substantial weight regain, reinforcing the importance of considering long-term weight-management strategies.

Common Mistakes With the Zepbound Dosing Schedule

Following the dosing schedule correctly can make treatment safer and more predictable.

Increasing too quickly

Moving through the doses faster than recommended can increase gastrointestinal side effects.

Assuming 15 mg is automatically best

The highest dose isn't necessarily the right dose for every patient. A lower maintenance dose may provide an excellent balance between effectiveness and tolerability.

Doubling after a missed injection

Never take extra medication to compensate for a missed dose.

Ignoring persistent side effects

Ongoing vomiting, severe abdominal pain, dehydration, or other concerning symptoms shouldn't simply be accepted as part of treatment.

Changing the dose without medical guidance

Your response to tirzepatide can change over time. Dose adjustments should be made with the prescribing clinician, particularly if you're also taking medication for diabetes or other conditions.

Tips for Getting the Most From Your Zepbound Treatment

A few habits can make the titration process easier:

Use the same day every week. A recurring phone reminder can help prevent missed doses.
Don't rush escalation. Give your body time to adjust to each strength.
Track side effects. Note nausea, constipation, appetite changes, and other symptoms after each injection.
Monitor your progress beyond the scale. Waist measurements, energy, appetite control, and metabolic markers can also provide useful information.
Prioritize protein and resistance training. Maintaining muscle is an important part of healthy weight loss.
Stay hydrated. This is particularly important if you're experiencing vomiting, diarrhea, or reduced food intake.
Discuss plateaus before increasing the dose. A temporary slowdown doesn't necessarily mean you need a higher dose.

Frequently Asked Questions

How long do you stay on each Zepbound dose?

The standard titration schedule keeps patients at each dose for at least four weeks before considering an increase.

Is 2.5 mg enough for weight loss?

2.5 mg is primarily the starter dose and is not one of the standard maintenance doses for weight management.

Is 7.5 mg a maintenance dose?

The standard FDA-approved maintenance doses are 5 mg, 10 mg, and 15 mg. The 7.5 mg strength is generally used as an intermediate step.

Is 12.5 mg a maintenance dose?

Like 7.5 mg, 12.5 mg is primarily an intermediate titration strength between standard maintenance doses.

Do you have to reach 15 mg?

No. Some patients achieve satisfactory results at 5 mg or 10 mg and remain at that dose under medical supervision.

Can you go back to a lower dose?

A lower dose may be appropriate if side effects become difficult to tolerate or if your treatment goals are being met at a lower strength. Discuss any dose reduction with your prescriber.

The Bottom Line

The Zepbound dosing schedule is designed around gradual progression rather than reaching the highest dose as quickly as possible. Treatment typically starts at 2.5 mg for four weeks, followed by 5 mg, with optional increases through 7.5 mg, 10 mg, 12.5 mg, and eventually 15 mg.

The most important distinction is that 5 mg, 10 mg, and 15 mg are the standard maintenance options, while 2.5 mg is the starter dose and 7.5 mg and 12.5 mg generally serve as transition strengths.

Clinical trials show that higher doses can produce greater average weight loss, but the difference between doses varies from person to person. The best dose is ultimately the one that provides meaningful results while remaining tolerable and medically appropriate.

If you're starting Zepbound, focus less on reaching 15 mg and more on finding a sustainable dose that works for your body, your goals, and your long-term treatment plan.

Sources

Eli Lilly. Zepbound (tirzepatide) injection prescribing information. Revised 2024.
Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. SURMOUNT-1. N Engl J Med. 2022;387:205-216.
Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes. SURMOUNT-2. Lancet. 2023;402:613-626.
Wadden TA, et al. Tirzepatide after intensive lifestyle intervention. SURMOUNT-3. Nat Med. 2023.
Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction. SURMOUNT-4. JAMA. 2024;331:38-48.
Malhotra A, et al. Tirzepatide for obstructive sleep apnea and obesity. SURMOUNT-OSA. N Engl J Med. 2024;391:1193-1205.
Singh S, et al. Skip-titration in GLP-1 receptor agonist therapy and adverse events. Obes Rev. 2024.
American Society of Anesthesiologists. Consensus-based guidance on preoperative management of patients on GLP-1 receptor agonists. ASA. 2023.
U.S. Food and Drug Administration. Adverse Event Reporting System (FAERS) public dashboard, tirzepatide query, accessed Q1 2026.
Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. SURPASS-2. N Engl J Med. 2021;385:503-515.